Finanzen von Azenta, Inc. (AZTA)AZTAAzenta, Inc.

Azenta, Inc. (AZTA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Sample management solutions, accounting for 56.0% of total sales, equivalent to $81.09M. Another important revenue stream is Multiomics. Understanding this composition is critical for investors evaluating how AZTA navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Azenta, Inc. maintains a gross margin of 44.89%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2.27%, while the net margin is -0.95%. These profitability ratios, combined with a Return on Equity (ROE) of -7.04%, provide a clear picture of how effectively AZTA converts its operational activities into shareholder value.

In the context of the broader market, AZTA competes directly with industry leaders such as SNDA and PSNL. With a market capitalization of $1.65B, it holds a significant position in the sector. When comparing efficiency, AZTA's gross margin of 44.89% stands against SNDA's 100.00% and PSNL's 21.21%. Such benchmarking helps identify whether Azenta, Inc. is trading at a premium or discount relative to its financial performance.

Azenta reported a total revenue of $161 million in Q3 2026, a 12% year-over-year increase, and a non-GAAP EPS of $0.16, exceeding expectations by $0.06. However, the company has faced significant net income losses in previous quarters, including a net loss of $160.8 million in Q2 2026.